Evidence map›Paper›PMID 40936907›Full record

ReviewFrontiers in immunology2025

New dimensions of PD-1/PD-L1 inhibitor combination therapy in cancer treatment: current advances and future perspectives.

Cheng Tong, Yue Wu, Renzhao Wu

Abstract readReview
In one paragraph

Review in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Cheng Tong *First People's Hospital of Linping District, Hangzhou, China.
Yue Wu *The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, Zhejiang, China.
Renzhao WuThe Key Laboratory of Research and Development of Chinese Medicine of Zhejiang Province, Zhejiang Academy of Traditional Chinese Medicine, Tongde Hospital of Zhejiang Province, Hangzhou, Zhejiang, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The treatment of tumors remains one of the most challenging issues in modern medicine. For a long time, surgical intervention and radiochemotherapy were the primary methods employed to combat tumors; however, the therapeutic outcomes often fell short of expectations. Immunotherapy offers a promising alternative by enhancing the patient's immune system's ability to recognize and eliminate tumor cells while minimizing damage to normal cells and tissues. This advancement has brought new hope for cancer patients. In recent years, significant progress has been made in tumor immunotherapy with immune checkpoint inhibitors (ICIs), particularly Programmed Cell Death Protein-1 (PD-1)/Programmed Cell Death-Ligand 1 (PD-L1) inhibitors. An increasing number of researchers have discovered that combination therapy involving PD-1/PD-L1 inhibitors alongside chemotherapeutic agents or other types of ICIs yields more pronounced effects compared to monotherapy. Nevertheless, there remains a considerable risk of developing resistance and experiencing various adverse events. Traditional Chinese medicine (TCM) is frequently utilized as an adjunctive treatment for tumors due to its potential to enhance overall immune function in patients. Recent studies indicate that combining TCM with PD-1/PD-L1 inhibitors can significantly improve median survival times for patients, undoubtedly providing new directions for cancer treatment, however, there remains a lack of sufficient large-sample prospective controlled studies to provide evidence supporting the combined treatment of traditional Chinese medicine and immune checkpoint inhibitors for tumors. This study summarizes recent research on the combined use of PD-1/PD-L1 inhibitors with chemotherapeutic drugs, other ICIs, or TCM in cancer therapy. The aim is to explore their synergistic mechanisms and clinical application value while drawing greater attention from scholars to the significant value of traditional Chinese medicine in the combined treatment strategies for tumors. Additionally, this research provides insights into future prospects for anti-tumor research within TCM.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsB7-H1 AntigenImmune Checkpoint InhibitorsNeoplasmsProgrammed Cell Death 1 ReceptorAnimalsCombined Modality TherapyHumansImmunotherapyMedicine, Chinese TraditionalB7-H1 AntigenCD274 protein, humanImmune Checkpoint InhibitorsPDCD1 protein, humanProgrammed Cell Death 1 Receptorcombination therapyimmune checkpointimmune-related adverse events (IRAE)PD-1/PD-L1traditional Chinese medicine (TCM)

Identifiers

PMID40936907
PMCPMC12420611

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.